Skip to content
AnalystLens

Byrn, Inc.BRRN

Sector
Other
Industry
Services-Management Services
Exchange
OTC

Stock Price $BRRN

Latest filings

You are here#57 of 57 in Industrials by market cap

Filing record · 2020–202610-K910-Q108-K6

BRRN filed 9 annual reports (10-K), 10 quarterly reports (10-Q) and 6 current reports (8-K) between 2020 and 2026.

  1. Change in control8-K · Feb ’21Feb ’21
  2. FY2024 annual report10-K · Apr ’25Apr ’25

01—Key figures

Source: 10-KFY2012
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  3. $21,000
YoY changeLatest −48.7%

Latest bar from 10-KFY2012Click a bar to open its SEC filing

View full history →
All BRRN Financial Metrics41 metrics

Income Statement14

Balance Sheet17

Cash Flow7

Per Share3

02—Overview

Byrn, Inc. Financial Overview 2021–2025

Updated Oct 10, 2026

Despite racking up a staggering accumulated deficit of over $117.5 milliona by Q3 2025, MEDO Technologies, Inc. (formerly Byrn, Inc.) has generated exactly $0 in revenue over the last half-decade. This total lack of commercial traction underscores a highly speculative investment thesis: the firm functions purely as a dormant shell attempting a high-wire pivot into an AI-driven pharmaceutical distributor. Surviving solely on interest-free related-party loans, MEDO remains entirely dependent on dilutive financing to fund its newly proposed acquisition strategy.

The operational timeline highlights persistent financial distress. The company's trajectory derailed after a voided share exchange triggered an $87.6 millionb goodwill impairment in FY2021, effectively halting operations. By the close of FY2025, the balance sheet had flatlined, reporting exactly $0 in total assets alongside a stockholders' deficit of $96,612. Recent quarters show widening cash burn under new management, with net losses accelerating to $178,646 in Q2 2026, a massive jump from just $8,472 in the same period a year earlier.

To pave the way for its strategic rebrand, ownership implemented a severe 1-for-100,000 reverse stock split in September 2026, following MEDO Healthcare LLC's purchase of voting control for a mere $175,000c in May 2026. Despite lacking tangible operations, speculative market activity valued the pre-revenue shell at $24 million at the close of FY2025, with shares trading at $0.06. With zero operating cash flow, future viability hinges entirely on unproven structural pivots.

Recent Developments (Q1 and Q2 2026)

Following a sweeping executive overhaul in May 2026, John Leo and Arthur Magee replaced David Lazar as CEO and CFO to spearhead the company's new strategic direction. Before his exit, Lazar settled $93,285d of related-party debt by receiving 30,015,577 newly issued shares, pushing the outstanding count to 450,000,000 in Q1 2026. During this period, the net loss widened to $30,937, up from $16,410 a year earlier. By Q2 2026, total liabilities swelled to $206,170 against a mere $1,909 in assets, prompting management to highlight severe material weaknesses in internal controls.

Bulls can argue that the injection of experienced corporate finance leadership provides a theoretical foundation for executing future acquisitions. Conversely, the stock appears vastly overvalued relative to recent performance, commanding a $56 millione market capitalization alongside $0.00 in annual EPS, resulting in an N/A P/E ratio as of August 14, 2026.

What to watch: progress on securing acquisition capital; remediation of internal control weaknesses under the new executive team

03—Filings

Recent SEC Filings

  1. 8-KByrn, Inc. 8-K Report, Bylaw Amendment (Sep 16, 2026)Byrn, Inc. (BRRN) has filed an 8-K announcing significant corporate changes set to take effect on September 23, 2026. Most notably, the company will undergo a substantial one-for-one-hundred-thousand (1-for-100,000) reverse stock split. This action is designed to dramatically reduce the number of outstanding shares. Additionally, the company will officially change its name to MEDO Technologies, Inc., and has applied to trade under the ticker symbol "MEDO". This reverse stock split is an aggressive move that will impact all shareholders. Those holding fewer than 100,000 shares prior to the split will receive a nominal cash payment of $0.00007 per share, effectively cashing them out. Holders of 100,000 or more shares will have fractional shares rounded up to the nearest whole share. The adjusted trading is expected to commence on the OTCID Market on September 24, 2026, with a new CUSIP number. Investors should carefully consider the implications of this significant share consolidation.
  2. 8-KByrn, Inc. 8-K Report, Change in Control (May 11, 2026)Byrn, Inc. (BRRN) has undergone a significant change in control and leadership. MEDO Healthcare LLC has acquired a controlling stake of approximately 84.7% of the company's voting power through the purchase of 10 million shares of Series A-1 Preferred Stock for $175,000. This transaction, which occurred on April 24, 2026, has resulted in a substantial shift in beneficial ownership, with Jean Christophe Chopin now holding 63.1% of the common stock, but MEDO Healthcare LLC wielding dominant voting power due to the preferred stock. Concurrently, David Lazar has resigned as the sole director and officer. John Leo has been appointed as the new Chief Executive Officer and sole director, and Arthur Magee has been appointed as CFO and Secretary. Both Leo and Magee bring extensive experience in investment banking and corporate finance from Primary Capital LLC, suggesting a strategic focus on financial operations and potential growth initiatives.
  3. 8-KByrn, Inc. 8-K Report, Material Agreement (Feb 16, 2021)This 8-K filing from Born, Inc. (BRRN) details a significant corporate transformation, primarily through a share exchange agreement with Alkeon Creators, Inc. effective February 16, 2021. This transaction has been accounted for as a recapitalization, with Alkeon being the accounting acquirer. This strategic move has effectively resulted in a reverse merger, with the former stockholders of Alkeon now holding a majority of the outstanding common stock and Born, Inc. ceasing to be a shell company. The company has also undergone a name change from Quture International, Inc. to Born Inc. and a 1-for-1,000 reverse stock split. The company is repositioning itself as a holding company specializing in digital, data-led solutions for retail supply chains, operating through its subsidiary Alkeon. Alkeon provides B2B solutions for digitizing tradeshows and showrooms, alongside the Born.com platform that connects luxury design brands with retailers. The business model is primarily subscription-based. The filing also highlights a change in leadership with Mr. Jean Christophe Chopin appointed as the sole officer and director, replacing Mr. Wieland Kreuder.
  4. 8-KByrn, Inc. 8-K Report, Bylaw Amendment (Feb 10, 2021)Born, Inc. (BRRN) has filed an 8-K report to announce a significant change in its fiscal year-end. Effective February 4, 2021, the company's Board of Directors approved the shift of its fiscal year-end from its previous date to December 31st. This strategic decision aims to align the company's reporting calendar with that of its intended subsidiary, Alkeaon Creators Inc. This alignment is crucial for streamlining financial reporting and operational management as the company potentially integrates Alkeaon Creators Inc. Investors should note this change as it will impact the timing of future financial statements and reporting periods. The company has also provided the relevant Board of Directors' resolutions as an exhibit to this filing, supporting the official nature of this change. No other material financial or operational updates were disclosed in this filing.
  5. 8-KByrn, Inc. 8-K Report, Bylaw Amendment (Dec 1, 2020)Byrn, Inc. (BRRN), formerly Quture International, Inc., has filed an 8-K report detailing significant corporate actions taken on November 24, 2020, and effective December 1, 2020. The company has officially changed its name to Byrn, Inc. and executed a 1-for-1,000 reverse stock split. These changes are strategically positioned in anticipation of the company entering a new line of business operations. Investors should note that FINRA has declared these changes effective as of December 1, 2020. Furthermore, the company was informed that its ticker symbol will be updated to BRRN within twenty business days. This rebranding and restructuring signals a potential shift in the company's strategic direction, and investors should monitor future filings for details regarding the new business ventures.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.